|
|
J Psychiatry Neurosci. 1994 March; 19(2): 114–119. | PMCID: PMC1188575 |
Tryptophan in the treatment of late luteal phase dysphoric disorder: a pilot study. S Steinberg, L Annable, S N Young, and M C Bélanger St. Mary's Hospital, Montréal, Quebec, Canada. Abstract Thirteen patients diagnosed during two menstrual cycles as suffering from late luteal phase dysphoric disorder were then followed in an open pilot study for a further three cycles. During one complete cycle, baseline levels of symptoms were obtained. During the next three cycles, the patients were treated with L-tryptophan, six grams per day. L-tryptophan treatment was associated with a significant amelioration of symptoms with only mild side effects. These data suggest that L-tryptophan should be tested at a dose of six grams of L-tryptophan per day in a placebo-controlled study in patients with late luteal phase dysphoric disorder who suffer from symptoms such as depression, irritability, insomnia and carbohydrate craving, which may respond to potentiation of serotonin function. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (998K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. Images in this article Click on the image to see a larger version. These references are in PubMed. This may not be the complete list of references from this article. - BECK AT, WARD CH, MENDELSON M, MOCK J, ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561–571. [PubMed]
- Brzezinski AA, Wurtman JJ, Wurtman RJ, Gleason R, Greenfield J, Nader T. d-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet Gynecol. 1990 Aug;76(2):296–301. [PubMed]
- Denckla WD, Dewey HK. The determination of tryptophan in plasma, liver, and urine. J Lab Clin Med. 1967 Jan;69(1):160–169. [PubMed]
- Halbreich U, Endicott J, Lesser J. The clinical diagnosis and classification of premenstrual changes. Can J Psychiatry. 1985 Nov;30(7):489–497. [PubMed]
- Harrison WM, Endicott J, Rabkin JG, Nee J. Treatment of premenstrual dysphoric changes: clinical outcome and methodological implications. Psychopharmacol Bull. 1984 Winter;20(1):118–122. [PubMed]
- Henry GM, Weingartner H, Murphy DL. Influence of affective states and psychoactive drugs on verbal learning and memory. Am J Psychiatry. 1973 Sep;130(9):966–971. [PubMed]
- Menkes DB, Taghavi E, Mason PA, Spears GF, Howard RC. Fluoxetine treatment of severe premenstrual syndrome. BMJ. 1992 Aug 8;305(6849):346–347. [PMC free article] [PubMed]
- Moos RH. The development of a menstrual distress questionnaire. Psychosom Med. 1968 Nov–Dec;30(6):853–867. [PubMed]
- Morand C, Young SN, Ervin FR. Clinical response of aggressive schizophrenics to oral tryptophan. Biol Psychiatry. 1983 May;18(5):575–578. [PubMed]
- Sinha YN, Selby FW, Lewis UJ, VanderLaan WP. A homologous radioimmunoassay for human prolactin. J Clin Endocrinol Metab. 1973 Mar;36(3):509–516. [PubMed]
- Steinberg S. The treatment of late luteal phase dysphoric disorder. Life Sci. 1991;49(11):767–802. [PubMed]
- Sundblad C, Modigh K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand. 1992 Jan;85(1):39–47. [PubMed]
- Wilkins K, Wigle D. Eosinophilia-myalgia syndrome. CMAJ. 1990 Jun 1;142(11):1265–1266. [PMC free article] [PubMed]
- Wood SH, Mortola JF, Chan YF, Moossazadeh F, Yen SS. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol. 1992 Sep;80(3 Pt 1):339–344. [PubMed]
|
